A Study Assessing the Impact of HLA-Sensitization on Clinical Outcomes of Conversion from Calcineurin Inhibitor to Belatacept-Based Immunosuppression in Kidney Transplant Recipients
Phase of Trial: Phase IV
Latest Information Update: 19 Sep 2019
Price : $35 *
At a glance
- Drugs Belatacept (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 19 Sep 2019 Results published in the Transplantation.
- 13 Jul 2018 New trial record
- 06 Jun 2018 Results presented at the 2018 American Transplant Congress.